- SS Innovations is scaling its SSi Mantra surgical robotic system from an established Indian base into international markets.
- Second-quarter revenue rose 39.4% year over year to $13.9 million, while 30 SSi Mantra systems were installed during the quarter.
- The company entered the second half of 2026 with 224 systems installed across 12 countries and more than 12,000 cumulative procedures.
- Potential regulatory clearance in the United States and CE marking in Europe could materially enlarge SSII’s addressable market.
- The investment case is seen as attractive because SSII is still early in its commercialization curve, although investors must weigh cash consumption, regulatory risk, and potential dilution against its growth prospects.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, presents an attractive proposition for investors in the medical-technology sector. The company’s SSi Mantra system is being deployed at an increasing number of hospitals, surgeons are performing thousands of procedures with the platform, and SSII is beginning to establish an installed base outside its home market.
The latest quarterly figures show a company rapidly expanding from a relatively small original base. SSII reported second-quarter revenue of $13.9 million, an increase of 39.4% from the same period a year earlier. It installed 30 SSi Mantra systems during the quarter, compared with 23 in Q2 2025. First-half revenue reached $25 million, up 65.6% year over year.
As of June 30, the cumulative installed base had reached 224 systems across 12 countries. Hospitals using the platform had performed 12,272 procedures, including 637 cardiac operations, 222 pediatric procedures and 175 telesurgeries.
Those numbers provide important context for a recent Seeking Alpha analysis by Eborose Capital, which argues that SSII offers investors a potentially more asymmetric opportunity than the much larger Intuitive Surgical (NASDAQ: ISRG) (https://ibn.fm/Y2kq3).
The comparison is useful, but the more important point is what it says about SSII itself. Intuitive Surgical has an enormous installed base and a mature recurring-revenue model built around its da Vinci platform. SS Innovations is at an earlier stage. Its installed base is much smaller, but that also means there is considerably more room for expansion if the company can continue converting hospitals and surgeons to its technology.
The growth differential is already visible. SSII’s installed base increased from 105 systems at the end of Q2 2025 to 224 one year later, while quarterly procedures climbed from 1,042 to 2,528. System sales generated $12.4 million of Q2 revenue, up 40.8% year over year.
For an emerging medical-device company, utilization is particularly important. Selling a robot creates the installed base; procedures performed on that robot create opportunities for recurring instrument and service revenue. That is one reason SSII’s longer-term economics could look different from today’s revenue mix.
It would be a mistake, however, to characterize SS Innovations simply as a lower-cost alternative to Intuitive Surgical. Price is part of the company’s strategy, particularly in India and other healthcare markets where the capital cost of robotic surgery can limit adoption. But the more significant investment argument is whether SSi Mantra provides the capabilities hospitals and surgeons actually require.
The company’s current SSi Mantra 3 platform incorporates an open-face surgeon console with a large 3D 4K monitor, ergonomic hand controls and head-tracking technology. Its patient-side carts are modular, while the vision cart incorporates 3D 4K imaging and other operating-room equipment.
SS Innovations also supports multiple specialties, including urology, gynecology, general surgery, thoracic surgery and cardiac surgery. The company says the system is designed to give surgeons flexibility in configuring the robotic arms according to the procedure. That breadth is important because the economic value of a surgical robot ultimately depends on utilization. As an example of its growing utilization, a medical team in India utilized the SSi Mantra surgical robotic systems to successfully complete fifty gastric bypass procedures in a single day, demonstrating the robustness of the company’s technology.
India is particularly significant to the SSII story. The country has a huge population and a healthcare system in which access to advanced medical technology varies considerably between institutions and regions. SS Innovations has built its commercial operation in that environment rather than waiting for entry into the world’s largest developed healthcare markets. That has allowed the company to establish clinical experience while expanding its installed base.
The company’s own development history also provides a degree of credibility. Founder, Chairman and CEO Dr. Sudhir Srivastava is a robotic cardiac surgeon, and the company’s technology has been developed with applications in cardiac surgery alongside other specialties. SS Innovations also operates a training infrastructure intended to help surgeons transition to robotic procedures.
Telesurgery adds another dimension. In July, surgeons used SSi Mantra to conduct a robotic sleeve gastrectomy between Colombia and India across more than 13,600 miles of fiber-network distance, according to the company’s SEC filing.
The biggest potential change to SSII’s growth profile could come from outside India. The company is pursuing U.S. FDA 510(k) clearance and European CE marking for SSi Mantra. Those approvals would give SSII access to markets where robotic surgery is already well established and where hospitals have demonstrated willingness to invest in robotic-assisted procedures.
Importantly, much of SSII’s current growth has been achieved without access to the U.S. market. If the company eventually receives the necessary regulatory clearances, the potential market expands substantially beyond the countries in which it currently operates.
For more information, visit the company’s website at www.SSInnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
